LENZ Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

LENZ Therapeutics (Nasdaq: LENZ) announced management will present at two investor conferences in early March 2026: TD Cowen on March 2 (Boston) and Leerink Partners on March 10 (Miami).

Both events include fireside chats with live audio webcasts and 1x1 investor meetings; replays will be available on the company website for 12 months.

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ^® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:

TD Cowen 46th Annual Health Care Conference
Date: March 2, 2026
Location: Boston, MA
Format: Fireside chat at 9:50am ET (live audio webcast) and 1x1 investor meetings

Leerink Partners 2026 Global Healthcare Conference
Date: March 10, 2026
Location: Miami, FL
Format: Fireside chat at 10:00am ET (live audio webcast) and 1x1 investor meetings

Live audio webcasts will also be available on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcasts will be available on the Company’s website for 12 months following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

FAQ

When will LENZ Therapeutics present at the TD Cowen conference and how can investors listen?

LENZ will present on March 2, 2026 at TD Cowen with a fireside chat at 9:50am ET. According to the company, the session will be streamed as a live audio webcast and available for replay on the LENZ investor website for 12 months.

What are the details for LENZ Therapeutics' presentation at Leerink Partners on March 10, 2026?

LENZ management will present at Leerink Partners on March 10, 2026 with a fireside chat at 10:00am ET. According to the company, the event includes a live audio webcast plus scheduled 1x1 investor meetings and a replay posted on the company site.

Where can shareholders find the LENZ Therapeutics live webcasts and replays for the March 2026 conferences?

Live audio webcasts and replays will be posted in the Investors & Media section at www.LENZ-tx.com. According to the company, replays of both conference webcasts will remain available on the website for 12 months after each event.

Will LENZ Therapeutics management hold investor one-on-one meetings at the March 2026 conferences?

Yes, management will conduct 1x1 investor meetings at both TD Cowen (March 2) and Leerink Partners (March 10). According to the company, these meetings are scheduled alongside the fireside chats to engage directly with institutional and accredited investors.

Does LENZ Therapeutics mention its approved product VIZZ in the March 2026 conference notices and why it matters to investors?

The notice highlights VIZZ (aceclidine 1.44%) as the first FDA-approved aceclidine eye drop for presbyopia. According to the company, management presentations will likely cover commercial progress and context for VIZZ during investor Q&A at the conferences.